Castle Creek Pharma, a Parsippany, New Jersey and Chicago, Illinois-based biopharmaceutical company developing innovative therapies for patients with rare, serious or debilitating dermatologic conditions, received $71.8m in funding.
Backers included Fidelity Management & Research Company and Valor Equity Partners.
The company intends to use the funds to continue to develop CCP-020 as an important treatment for EBS, a form of Epidermolysis Bullosa (EB), a rare genetic condition that causes fragile skin that leads to painful blisters. There are currently no FDA approved treatment options for any form of EB, including EBS.
Led by Michael Derby, co-founder and chief executive officer, Castle Creek Pharma Castle Creek is a company dedicated to developing therapies for patients with orphan dermatologic and other underserved conditions.
With this new capital, the company has invested a total of $122.5 million into the development of innovative therapies for patients with rare dermatologic conditions including EBS. It is a Paragon portfolio company.